Cetera Advisor Networks’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-4,811
Closed -$557K 2912
2023
Q3
$557K Sell
4,811
-852
-15% -$91.5K ﹤0.01% 1698
2023
Q2
$582K Sell
5,663
-1,017
-15% -$107K ﹤0.01% 1621
2023
Q1
$729K Sell
6,680
-2,298
-26% -$254K 0.01% 1438
2022
Q4
$1.02M Buy
8,978
+4,116
+85% +$342K 0.01% 1183
2022
Q3
$301K Sell
4,862
-577
-11% -$40.3K ﹤0.01% 1598
2022
Q2
$434K Sell
5,439
-586
-10% -$55.5K 0.01% 1364
2022
Q1
$634K Buy
6,025
+255
+4% +$24.9K 0.01% 1152
2021
Q4
$622K Buy
5,770
+262
+5% +$28.6K 0.01% 1152
2021
Q3
$603K Sell
5,508
-634
-10% -$65.8K 0.01% 1113
2021
Q2
$575K Buy
6,142
+1,121
+22% +$103K 0.01% 1099
2021
Q1
$462K Buy
5,021
+1,012
+25% +$85.4K 0.01% 916
2020
Q4
$293K Buy
4,009
+930
+30% +$69.1K 0.01% 1060
2020
Q3
$239K Buy
3,079
+69
+2% +$4.75K 0.01% 1068
2020
Q2
$167K Buy
+3,010
New +$129K ﹤0.01% 1219

Other funds holding HZNP

Cetera Advisor Networks's HZNP Position: Q4 2023 in Review

Cetera Advisor Networks sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 4,811 shares — an estimated $557K sold.

Cetera Advisor Networks first reported a position in HZNP in Q2 2020 and held it in 14 quarters. The position peaked at $1.02M in Q4 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Cetera Advisor Networks reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Cetera Advisor Networks sold 4,811 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $557K.
  • Cetera Advisor Networks first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2020 and held it in 14 quarters.
  • Cetera Advisor Networks's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.02M in Q4 2022.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Cetera Advisor Networks's 13F filing for Q4 2023, filed 13 Feb 2024.